Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402181 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00402181 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 53 participants.
The verdict
NCT00402181, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer that does not respond to treatment) multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\]).
Interventions
- DRUG Dexamethasone
- BIOLOGICAL Siltuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402181
The ClinicalTrials.gov registry entry for NCT00402181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00402181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402181 about?
NCT00402181 is a clinical study titled "An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer that does not respond to treatment) multiple myeloma (a type of cancer th...
What is the current status of trial NCT00402181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2006-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00402181?
The interventions under investigation include: Dexamethasone (DRUG), Siltuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00402181?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.